Immune evasion by HIV-1 accessory proteins likely contributes to the failure of host immunity to control the infection and may complicate approaches to eradication. We will test the hypothesis that inhibiting viral evasion of host immunity can contribute to a curative treatment strategy. Recent data suggest that reactivation of viral gene expression is not sufficient to cause the death of cells latently infected with HIV-1 cell-death requires the killing-activity of cytotoxic T lymphocytes (CTL). Consequently, our strategy focuses on HIV-1 Nef, which provides viral evasion of CTL-activity. Nef prevents class I MHC from reaching the plasma membrane, decreasing the concentration of viral antigens at the cell surface and inhibiting the killing of infected cells by CTL. Interference with this activity o Nef should empower CTL and facilitate the eradication of infected cells from the host. In principle, this strategy applies to "reservoir" cells expressing low levels of viral antigens as well as to CD-positive memory T cells in which latent virus is reactivated pharmacologically. During the R21 phase of this proposal, we will validate the importance of Nef in viral resistance to eradication by showing that primary T cells in which virus is reactivated from latency display reduced surface levels of MHC-I and that this reduction is Nef-dependent and associated with resistance to CTL-mediated killing. Concurrently, we will use our recent knowledge of how Nef modulates MHC-I at the molecular and structural levels to identify small molecules capable of inhibiting this activity. We will exploit our X-ray crystallographic model of the complex formed by Nef, the cytoplasmic domain of the MHC-I ?-chain, and the ? subunit of the endosomal clathrin adaptor AP1 to design prototypic peptide inhibitors and to devise a high throughput screen capable of identifying small molecule lead compounds. During the R33 phase, we will broaden our approach to drug discovery by including a novel computational method that matches semi-rigid scaffold molecules displaying amino acid R groups to the structure of the complex. We will evaluate leads from this approach as well as from our high throughput screen using cell- based secondary screens and optimize them structurally. Lastly, we will use these small molecules in in vitro, ex vivo, and in vivo settings o establish that inhibiting Nef-mediated immune evasion can facilitate viral eradication.

Public Health Relevance

HIV-1 infection is typically not cured despite drug-therapy that reduces viral replication to nearly undetectable levels, because reservoirs of virus persist in the host. These reservoirs persist partly because of the virus's ability to evade host defenses via the action of proteins that antagonize specific aspects of immunity. We will validate and develop the HIV-1 Nef protein as a new drug- target whose inhibition will empower a natural host defense, cytotoxic T lymphocytes, to kill infected cells and eradicate the infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI110162-01
Application #
8656289
Study Section
Special Emphasis Panel (ZAI1-JRR-A (S4))
Program Officer
Sharma, Opendra K
Project Start
2013-12-01
Project End
2015-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
1
Fiscal Year
2014
Total Cost
$236,345
Indirect Cost
$43,120
Name
Veterans Medical Research Fdn/San Diego
Department
Type
DUNS #
933863508
City
San Diego
State
CA
Country
United States
Zip Code
92161